董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jay Venkatesan | 男 | Director | 53 | 22.22万美元 | 10.04 | 2025-09-26 |
| Gregory H. Bailey | 男 | Director | 69 | 8.26万美元 | 87.36 | 2025-09-26 |
| Balkrishan Gill | 男 | Director and Executive Chairman of the Board | 60 | 30.00万美元 | 14.24 | 2025-09-26 |
| Stephen Brannan | 男 | Director | 68 | 25.54万美元 | 未持股 | 2025-09-26 |
| Balkishan Gill | 男 | Director and Executive Chairman of the Board | 61 | 未披露 | 未持股 | 2025-09-26 |
| Richard Marshall | 男 | Director | 57 | 8.26万美元 | 1.33 | 2025-09-26 |
| Steve Ledger | 男 | Chief Executive Officer and Director | 65 | 63.75万美元 | 31.95 | 2025-09-26 |
| Steve Ledger | 男 | Chief Executive Officer and Director | 65 | 未披露 | 未持股 | 2025-09-26 |
| Karen Wilson | 女 | Director | 62 | 24.01万美元 | 未持股 | 2025-09-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Balkrishan Gill | 男 | Director and Executive Chairman of the Board | 60 | 30.00万美元 | 14.24 | 2025-09-26 |
| Gregory S. Curhan | 男 | Chief Financial Officer | 63 | 170.04万美元 | 未持股 | 2025-09-26 |
| Randall Moreadith | 男 | Chief Development Officer | 71 | 56.32万美元 | 51.53 | 2025-09-26 |
| Balkrishan Gill | 男 | Director and Executive Chairman of the Board | 61 | 未披露 | 未持股 | 2025-09-26 |
| Steve Ledger | 男 | Chief Executive Officer and Director | 65 | 63.75万美元 | 31.95 | 2025-09-26 |
| Gregory S. Curhan | 男 | Chief Financial Officer | 63 | 未披露 | 未持股 | 2025-09-26 |
| Srini Tenjarla | 男 | SVP CMC & Formulation | 63 | 52.74万美元 | 8.22 | 2025-09-26 |
董事简历
中英对照 | 中文 | 英文- Jay Venkatesan
-
Jay Venkatesan自2017年7月Nivalis和Private Alpine完成合并以来，一直担任Alpine Immune Sciences, Inc.的董事会成员，担任Alpine Immune科学公司，Inc.于2017年7月至2018年8月担任总裁，此前曾于2015年11月至2016年6月担任Private Alpine的首席执行官，并于2016年6月至2017年7月担任Private Alpine的总裁。自2015年11月以来，Venkatesan博士还担任Private Alpine的董事会成员。自2018年5月以来，Venkatesan博士一直担任私营制药公司Angion Biomedica公司的首席执行官和董事会成员。在加入Private Alpine之前，Venkatesan博士是Oncothyreon，Inc.（现为Cascadian治疗）的执行副总裁兼总经理，在Oncothyreon收购Alpine Biosciences后，该公司于2018年3月被Seattle Genetics，Inc.收购，2014年8月至2015年5月，他曾担任联合创始人兼首席执行官。此前，Venkatesan博士曾于2008年至2013年担任全球医疗保健股票基金Ayer Capital Management的创始人、投资组合经理和董事总经理。在此之前，他于2002年至2007年担任Brookside Capital Partners的董事。在他职业生涯的早期，Venkatesan博士于1995年至1996年在Partricof & Co. Ventures从事医疗保健投资，并于1993年至1995年在麦肯锡公司从事咨询工作。Venkatesan博士目前是Alpine Bioventures的管理合伙人。此外，Venkatesan博士目前在CellBiotherapy和Exicure治疗（纳斯达克股票代码：XCUR）的董事会任职。Venkatesan博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位和文学学士学位。威廉姆斯学院化学博士。
Jay Venkatesan has served as a member of Elicio's Board of Directors since June 2023 and previously served as Chairman of Angion's Board of Directors from January 2022 until the Merger. From May 2018 to June 2023, Dr. Venkatesan served as Angion's President and Chief Executive Officer. Dr. Venkatesan has served as a Managing Partner of Alpine BioVentures, an investment firm, since July 2015. From July 2015 to August 2018, Dr. Venkatesan was Co Founder and President of Alpine Immune Sciences, Inc., an immunotherapy company acquired by Vertex Pharmaceuticals in May 2024, and served as its Chief Executive Officer from July 2015 to June 2016. Additionally, from January 2014 to August 2014, Dr. Venkatesan served as Founder and Chief Executive Officer of Alpine BioSciences, Inc., a biotechnology company, which was acquired by Cascadian Therapeutics, Inc. From January 2008 to July 2015, Dr. Venkatesan served as the Founder and Managing Member of Ayer Capital, a global healthcare investment fund. Prior to that, Dr. Venkatesan served for six years as a director at Brookside Capital, the hedge fund subsidiary of Bain Capital, where he co managed healthcare investments. Dr. Venkatesan was also a consultant at McKinsey & Company, a consulting firm, and a venture investor with Apax Partners, an investment firm. Since 2018, Dr. Venkatesan has served on the board of Zylem Biosciences, Inc., a private biotechnology company. Since March 2025, Dr. Venkatesan has served on the board and as Chairman of the Nominating and Corporate Governance Committee of Serina Therapeutics, Inc., a public company focused on a developing drug optimization technology. Dr. Venkatesan previously served on the board of Alpine Immune Sciences, Inc. (acquired by Vertex Pharmaceuticals Incorporated) from June 2015 to July 2022, Iovance Biotherapeutics Inc. from 2013 to 2018, and Cell Biotherapies, Inc. from 2015 until its acquisition by Vaxanix Bio, Ltd. in 2023. Dr. Venkatesan has an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.A. from Williams College. - Jay Venkatesan自2017年7月Nivalis和Private Alpine完成合并以来，一直担任Alpine Immune Sciences, Inc.的董事会成员，担任Alpine Immune科学公司，Inc.于2017年7月至2018年8月担任总裁，此前曾于2015年11月至2016年6月担任Private Alpine的首席执行官，并于2016年6月至2017年7月担任Private Alpine的总裁。自2015年11月以来，Venkatesan博士还担任Private Alpine的董事会成员。自2018年5月以来，Venkatesan博士一直担任私营制药公司Angion Biomedica公司的首席执行官和董事会成员。在加入Private Alpine之前，Venkatesan博士是Oncothyreon，Inc.（现为Cascadian治疗）的执行副总裁兼总经理，在Oncothyreon收购Alpine Biosciences后，该公司于2018年3月被Seattle Genetics，Inc.收购，2014年8月至2015年5月，他曾担任联合创始人兼首席执行官。此前，Venkatesan博士曾于2008年至2013年担任全球医疗保健股票基金Ayer Capital Management的创始人、投资组合经理和董事总经理。在此之前，他于2002年至2007年担任Brookside Capital Partners的董事。在他职业生涯的早期，Venkatesan博士于1995年至1996年在Partricof & Co. Ventures从事医疗保健投资，并于1993年至1995年在麦肯锡公司从事咨询工作。Venkatesan博士目前是Alpine Bioventures的管理合伙人。此外，Venkatesan博士目前在CellBiotherapy和Exicure治疗（纳斯达克股票代码：XCUR）的董事会任职。Venkatesan博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位和文学学士学位。威廉姆斯学院化学博士。
- Jay Venkatesan has served as a member of Elicio's Board of Directors since June 2023 and previously served as Chairman of Angion's Board of Directors from January 2022 until the Merger. From May 2018 to June 2023, Dr. Venkatesan served as Angion's President and Chief Executive Officer. Dr. Venkatesan has served as a Managing Partner of Alpine BioVentures, an investment firm, since July 2015. From July 2015 to August 2018, Dr. Venkatesan was Co Founder and President of Alpine Immune Sciences, Inc., an immunotherapy company acquired by Vertex Pharmaceuticals in May 2024, and served as its Chief Executive Officer from July 2015 to June 2016. Additionally, from January 2014 to August 2014, Dr. Venkatesan served as Founder and Chief Executive Officer of Alpine BioSciences, Inc., a biotechnology company, which was acquired by Cascadian Therapeutics, Inc. From January 2008 to July 2015, Dr. Venkatesan served as the Founder and Managing Member of Ayer Capital, a global healthcare investment fund. Prior to that, Dr. Venkatesan served for six years as a director at Brookside Capital, the hedge fund subsidiary of Bain Capital, where he co managed healthcare investments. Dr. Venkatesan was also a consultant at McKinsey & Company, a consulting firm, and a venture investor with Apax Partners, an investment firm. Since 2018, Dr. Venkatesan has served on the board of Zylem Biosciences, Inc., a private biotechnology company. Since March 2025, Dr. Venkatesan has served on the board and as Chairman of the Nominating and Corporate Governance Committee of Serina Therapeutics, Inc., a public company focused on a developing drug optimization technology. Dr. Venkatesan previously served on the board of Alpine Immune Sciences, Inc. (acquired by Vertex Pharmaceuticals Incorporated) from June 2015 to July 2022, Iovance Biotherapeutics Inc. from 2013 to 2018, and Cell Biotherapies, Inc. from 2015 until its acquisition by Vaxanix Bio, Ltd. in 2023. Dr. Venkatesan has an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.A. from Williams College.
- Gregory H. Bailey
-
Gregory H. Bailey，是医学博士。担任Medivation, Inc.的董事会成员（2005年以来）。目前担任Medivation, Inc.薪酬委员会和审计委员会的成员。2007年1月以来，一直担任Palantir Group公司（生物技术商业银行）的管理合伙人。从2006年4月到2008年12月，曾任职Opexa Therapeutics公司（Opexa，上市细胞疗法公司）的董事会。从2004年5月到2007年1月，曾担任MDB Capital Group公司（一个投资银行公司）的董事总经理。此前，曾担任 Participating Capital公司（投资银行公司）的生命科学分析师（1995年以来）。持有Western Ontario大学的医学博士学位。
Gregory H. Bailey has served on the Board since Augt 2018 and served as the Chair of Board from October 2018 until May 2022. Dr. Bailey is currently executive chairman of Juvenescence Limited ("Juvenescence"). From October 2017 until January 2023, Dr. Bailey served as the chief executive officer of Juvenescence. Dr. Bailey is also a board director of Manx Financial Group, plc, BioHaven Ltd., and Portage Biotech, Inc. Dr. Bailey founded and served as a director of a number of private and public companies and previoly served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. Dr. Bailey practiced emergency medicine for 10 years before entering finance. Dr. Bailey received his M.D. from the University of stern Ontario. - Gregory H. Bailey，是医学博士。担任Medivation, Inc.的董事会成员（2005年以来）。目前担任Medivation, Inc.薪酬委员会和审计委员会的成员。2007年1月以来，一直担任Palantir Group公司（生物技术商业银行）的管理合伙人。从2006年4月到2008年12月，曾任职Opexa Therapeutics公司（Opexa，上市细胞疗法公司）的董事会。从2004年5月到2007年1月，曾担任MDB Capital Group公司（一个投资银行公司）的董事总经理。此前，曾担任 Participating Capital公司（投资银行公司）的生命科学分析师（1995年以来）。持有Western Ontario大学的医学博士学位。
- Gregory H. Bailey has served on the Board since Augt 2018 and served as the Chair of Board from October 2018 until May 2022. Dr. Bailey is currently executive chairman of Juvenescence Limited ("Juvenescence"). From October 2017 until January 2023, Dr. Bailey served as the chief executive officer of Juvenescence. Dr. Bailey is also a board director of Manx Financial Group, plc, BioHaven Ltd., and Portage Biotech, Inc. Dr. Bailey founded and served as a director of a number of private and public companies and previoly served as a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. Dr. Bailey practiced emergency medicine for 10 years before entering finance. Dr. Bailey received his M.D. from the University of stern Ontario.
- Balkrishan Gill
-
Balkrishan Gill自2017年7月以来一直担任我们的董事会成员。他是Evelo Biosciences公司的总裁、首席执行官和董事会成员（2015年6月以来）。自2015年以来，吉尔博士还曾担任Flagship Pioneural（一家创新企业，构思，创建，资源和发展一流的生命科学公司）的风险合伙人。从2016年到2019年，吉尔博士担任Realm Therapeutics plc的董事会成员。吉尔博士在伦敦国王学院（King&8217；s College）获得博士学位，并在INSEAD获得工商管理硕士学位。
Balkrishan Gill,is the Executive Chairman of Serina Therapeutics since 2024. Dr. Gill was the CEO of Evelo Biosciences from 2015 to 2023. During the same period Dr. Gill was a special advisor and senior partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and develops first-in-category life sciences companies. From 2016 to 2019, Dr. Gill served on the board of directors of Realm Therapeutics PLC. Dr. Gill received his Ph.D. from King's College, London and his MBA from INSEAD. - Balkrishan Gill自2017年7月以来一直担任我们的董事会成员。他是Evelo Biosciences公司的总裁、首席执行官和董事会成员（2015年6月以来）。自2015年以来，吉尔博士还曾担任Flagship Pioneural（一家创新企业，构思，创建，资源和发展一流的生命科学公司）的风险合伙人。从2016年到2019年，吉尔博士担任Realm Therapeutics plc的董事会成员。吉尔博士在伦敦国王学院（King&8217；s College）获得博士学位，并在INSEAD获得工商管理硕士学位。
- Balkrishan Gill,is the Executive Chairman of Serina Therapeutics since 2024. Dr. Gill was the CEO of Evelo Biosciences from 2015 to 2023. During the same period Dr. Gill was a special advisor and senior partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and develops first-in-category life sciences companies. From 2016 to 2019, Dr. Gill served on the board of directors of Realm Therapeutics PLC. Dr. Gill received his Ph.D. from King's College, London and his MBA from INSEAD.
- Stephen Brannan
-
Stephen Brannan自2017年3月起担任首席医疗官。2016年7月至2017年2月，Brannan博士担任独立顾问。在此之前，他于2015年8月至2016年6月担任Forum Pharmaceuticals Inc.临床研究和医疗事务Vice President。2011年5月至2015年8月，Brannan博士担任Takeda Pharmaceutical Company的神经科学治疗主管。Brannan博士在Forum，Takeda，Novartis，Cyberonics和Eli Lilly担任多个职位的同时，一直积极参与多个重要中枢神经系统治疗药物的开发，包括Cymbalta，Exelon Patch，Trinlix和VNS，用于治疗抗药性抑郁症。在加入制药行业之前，Brannan博士在University of Texas Health Science Center at San Antonio Uthscsa的教员工作。Brannan博士在UTHSCSA接受精神病学培训，在哈佛学院（Harvard College）获得文学学士学位，并持有德克萨斯大学达拉斯健康科学中心（University of Texas Health Science Center at Dallas）（西南医学院）的医学博士学位。
Stephen Brannan has served as our Chief Medical Officer since March 2017. From July 2016 to February 2017 Dr. Brannan was an independent consultant. Prior to that, he served as the Vice President Clinical Research and Medical Affairs at Forum Pharmaceuticals Inc. from August 2015 to June 2016. From May 2011 to August 2015 Dr. Brannan served as the Therapeutic Head of Neuroscience at Takeda Pharmaceutical Company. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta, Exelon Patch, Trintellix, and VNS for Treatment Resistant Depression while holding various roles at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. Prior to joining the pharmaceutical industry, Dr. Brannan worked on the faculty at the University of Texas Health Science Center at San Antonio UTHSCSA. Dr. Brannan trained in psychiatry at UTHSCSA, received his A.B. from Harvard College and holds a M.D. degree from the University of Texas Health Science Center at Dallas (Southwestern Medical School). - Stephen Brannan自2017年3月起担任首席医疗官。2016年7月至2017年2月，Brannan博士担任独立顾问。在此之前，他于2015年8月至2016年6月担任Forum Pharmaceuticals Inc.临床研究和医疗事务Vice President。2011年5月至2015年8月，Brannan博士担任Takeda Pharmaceutical Company的神经科学治疗主管。Brannan博士在Forum，Takeda，Novartis，Cyberonics和Eli Lilly担任多个职位的同时，一直积极参与多个重要中枢神经系统治疗药物的开发，包括Cymbalta，Exelon Patch，Trinlix和VNS，用于治疗抗药性抑郁症。在加入制药行业之前，Brannan博士在University of Texas Health Science Center at San Antonio Uthscsa的教员工作。Brannan博士在UTHSCSA接受精神病学培训，在哈佛学院（Harvard College）获得文学学士学位，并持有德克萨斯大学达拉斯健康科学中心（University of Texas Health Science Center at Dallas）（西南医学院）的医学博士学位。
- Stephen Brannan has served as our Chief Medical Officer since March 2017. From July 2016 to February 2017 Dr. Brannan was an independent consultant. Prior to that, he served as the Vice President Clinical Research and Medical Affairs at Forum Pharmaceuticals Inc. from August 2015 to June 2016. From May 2011 to August 2015 Dr. Brannan served as the Therapeutic Head of Neuroscience at Takeda Pharmaceutical Company. Dr. Brannan has been active in the development of multiple important central nervous system treatments including Cymbalta, Exelon Patch, Trintellix, and VNS for Treatment Resistant Depression while holding various roles at Forum, Takeda, Novartis, Cyberonics, and Eli Lilly. Prior to joining the pharmaceutical industry, Dr. Brannan worked on the faculty at the University of Texas Health Science Center at San Antonio UTHSCSA. Dr. Brannan trained in psychiatry at UTHSCSA, received his A.B. from Harvard College and holds a M.D. degree from the University of Texas Health Science Center at Dallas (Southwestern Medical School).
- Balkishan Gill
-
Balkrishan Gill自2024年4月起担任董事会成员。吉尔博士担任董事会执行主席。2015年至2023年担任Evelo Biosciences公司创始执行主席、总裁兼首席执行官、董事会成员。Gill博士还自2015年起担任Flagship Pioneering的风险合伙人，自2017年起担任Foghorn Therapeutics的董事会成员。2016年至2019年，Gill博士在Realm Therapeutics PLC担任董事。从2006年到2015年，吉尔博士担任moksha8 Pharmaceuticals，Inc.的总裁兼首席执行官，并担任TPG Growth的合伙人。在担任这些职务之前，吉尔博士曾于1997年至2006年担任Maxygen的总裁兼首席财务官，在此之前担任Valentis和Systemix的企业发展主管。他曾在勃林格曼海姆担任Recormon全球营销联席主管、北非主管和Elecsys免疫诊断平台企业发展主管。吉尔博士是一名免疫学家，根据在Celltech所做的工作，他在伦敦国王学院获得了关于抗体药物发现开发的早期工作的博士学位。他获得了欧洲工商管理学院的工商管理硕士学位。曾在世界各地、拉丁美洲、欧洲、中东、亚洲、非洲多个国家和地区生活、工作。
Balkrishan Gill has served on the Board since April 2024. Dr. Gill serves as the Executive Chairman of the Board. He served as the founding executive chair, president and chief executive officer, and a member of the board of directors of Evelo Biosciences, Inc. from 2015 to 2023. Dr. Gill has also served as a Venture Partner at Flagship Pioneering since 2015, and a member of the board of directors of Foghorn Therapeutics from 2017. From 2016 to 2019, Dr. Gill served as a director at Realm Therapeutics PLC. From 2006 to 2015, Dr. Gill served as the president and chief executive officer of moksha8 Pharmaceuticals, Inc., and as a partner at TPG Growth. Prior to these roles Dr. Gill was president and CFO at Maxygen from 1997 to 2006 and before that head of corporate development at Valentis and at Systemix. He worked at Boehringer Mannheim as co head of Global Marketing for Recormon, head of North Africa and head of corporate development for the Elecsys Immunodiagnostic Platform. Dr. Gill is an immunologist and received his Ph.D. for early work on antibody drug discovery development from King’s College, London based on work done at Celltech. He received his M.B.A. from INSEAD. He has lived and worked in many countries and locations across the , Latin America, Europe, the Middle East, Asia, and Africa. - Balkrishan Gill自2024年4月起担任董事会成员。吉尔博士担任董事会执行主席。2015年至2023年担任Evelo Biosciences公司创始执行主席、总裁兼首席执行官、董事会成员。Gill博士还自2015年起担任Flagship Pioneering的风险合伙人，自2017年起担任Foghorn Therapeutics的董事会成员。2016年至2019年，Gill博士在Realm Therapeutics PLC担任董事。从2006年到2015年，吉尔博士担任moksha8 Pharmaceuticals，Inc.的总裁兼首席执行官，并担任TPG Growth的合伙人。在担任这些职务之前，吉尔博士曾于1997年至2006年担任Maxygen的总裁兼首席财务官，在此之前担任Valentis和Systemix的企业发展主管。他曾在勃林格曼海姆担任Recormon全球营销联席主管、北非主管和Elecsys免疫诊断平台企业发展主管。吉尔博士是一名免疫学家，根据在Celltech所做的工作，他在伦敦国王学院获得了关于抗体药物发现开发的早期工作的博士学位。他获得了欧洲工商管理学院的工商管理硕士学位。曾在世界各地、拉丁美洲、欧洲、中东、亚洲、非洲多个国家和地区生活、工作。
- Balkrishan Gill has served on the Board since April 2024. Dr. Gill serves as the Executive Chairman of the Board. He served as the founding executive chair, president and chief executive officer, and a member of the board of directors of Evelo Biosciences, Inc. from 2015 to 2023. Dr. Gill has also served as a Venture Partner at Flagship Pioneering since 2015, and a member of the board of directors of Foghorn Therapeutics from 2017. From 2016 to 2019, Dr. Gill served as a director at Realm Therapeutics PLC. From 2006 to 2015, Dr. Gill served as the president and chief executive officer of moksha8 Pharmaceuticals, Inc., and as a partner at TPG Growth. Prior to these roles Dr. Gill was president and CFO at Maxygen from 1997 to 2006 and before that head of corporate development at Valentis and at Systemix. He worked at Boehringer Mannheim as co head of Global Marketing for Recormon, head of North Africa and head of corporate development for the Elecsys Immunodiagnostic Platform. Dr. Gill is an immunologist and received his Ph.D. for early work on antibody drug discovery development from King’s College, London based on work done at Celltech. He received his M.B.A. from INSEAD. He has lived and worked in many countries and locations across the , Latin America, Europe, the Middle East, Asia, and Africa.
- Richard Marshall
-
Richard Marshall自2024年3月起在董事会任职。他自2023年1月起担任Juvenescence首席执行官。Marshall博士是一位内科科学家和经验丰富的高管，在制药研发领域拥有20年的领导记录。从2019年9月到2023年1月，Marshall博士在阿斯利康公司担任高级副总裁兼呼吸与免疫学开发全球负责人，负责监督五种新药的开发和批准。这包括SARS COV2疫苗、Vaxzevria，和组合抗体，EVHIELDTM。2021年，他因对英国科学和应对COVID 19的贡献而获得英国女王荣誉名单的CBE认可。从2002年到2018年，Marshall博士在葛兰素史克公司担任越来越多的高级职务，包括纤维化研发副总裁。Marshall博士在伦敦大学学院获得神经科学理学学士、医学学士、外科学士和医学科学哲学博士学位，并曾在纽卡斯尔大学和皇家布朗普顿医院担任胸部医学客座教授和名誉顾问职务。马歇尔博士在《柳叶刀》和《新英格兰医学杂志》等杂志上共同撰写了60多篇原创出版物。
Richard Marshall has served on the Board since March 2024. He hasserved as the chief executive officer of Juvenescence since January 2023. Dr. Marshall is a physician scientist and highly experienced executive with a 20 year track record of leadership in pharmaceutical research & development. From September 2019 to January 2023, Dr. Marshall was senior vice president and Global Head of Respiratory & Immunology Development at AstraZeneca plc, overseeing the development and approval of five new medicines. This included the SARS CoV 2 vaccine, Vaxzevria, and combination antibody, EvhieldTM. In 2021 he was recognized in the Queen's Hons List with a CBE for his contribution to UK science and the COVID 19 response. From 2002 to 2018, Dr. Marshall held increasingly senior roles at GlaxoSmithKline plc, including vice president of Fibrosis R&D. Dr. Marshall received a Bachelor of Science in Neuroscience, a Bachelor of Medicine, a Bachelor of Surgery, and a Doctor of Philosophy in Medical Sciences from University College London and has held visiting professor and honorary consultant roles in thoracic medicine at Newcastle University and the Royal Brompton Hospital. Dr. Marshall has co authored more than 60 original publications in jnals including The Lancet and The New England Jnal of Medicine. - Richard Marshall自2024年3月起在董事会任职。他自2023年1月起担任Juvenescence首席执行官。Marshall博士是一位内科科学家和经验丰富的高管，在制药研发领域拥有20年的领导记录。从2019年9月到2023年1月，Marshall博士在阿斯利康公司担任高级副总裁兼呼吸与免疫学开发全球负责人，负责监督五种新药的开发和批准。这包括SARS COV2疫苗、Vaxzevria，和组合抗体，EVHIELDTM。2021年，他因对英国科学和应对COVID 19的贡献而获得英国女王荣誉名单的CBE认可。从2002年到2018年，Marshall博士在葛兰素史克公司担任越来越多的高级职务，包括纤维化研发副总裁。Marshall博士在伦敦大学学院获得神经科学理学学士、医学学士、外科学士和医学科学哲学博士学位，并曾在纽卡斯尔大学和皇家布朗普顿医院担任胸部医学客座教授和名誉顾问职务。马歇尔博士在《柳叶刀》和《新英格兰医学杂志》等杂志上共同撰写了60多篇原创出版物。
- Richard Marshall has served on the Board since March 2024. He hasserved as the chief executive officer of Juvenescence since January 2023. Dr. Marshall is a physician scientist and highly experienced executive with a 20 year track record of leadership in pharmaceutical research & development. From September 2019 to January 2023, Dr. Marshall was senior vice president and Global Head of Respiratory & Immunology Development at AstraZeneca plc, overseeing the development and approval of five new medicines. This included the SARS CoV 2 vaccine, Vaxzevria, and combination antibody, EvhieldTM. In 2021 he was recognized in the Queen's Hons List with a CBE for his contribution to UK science and the COVID 19 response. From 2002 to 2018, Dr. Marshall held increasingly senior roles at GlaxoSmithKline plc, including vice president of Fibrosis R&D. Dr. Marshall received a Bachelor of Science in Neuroscience, a Bachelor of Medicine, a Bachelor of Surgery, and a Doctor of Philosophy in Medical Sciences from University College London and has held visiting professor and honorary consultant roles in thoracic medicine at Newcastle University and the Royal Brompton Hospital. Dr. Marshall has co authored more than 60 original publications in jnals including The Lancet and The New England Jnal of Medicine.
- Steve Ledger
-
史蒂夫·莱杰自2022年12月起担任董事会成员。莱杰先生是公司的首席执行官。Ledger先生于2021年6月起担任Serina的首席财务官，直至2024年3月，他被任命为公司临时首席执行官。董事会于2024年9月9日任命莱杰先生为首席执行官。Ldger先生拥有超过35年的投资者、董事会成员、顾问经验，并在早期公司担任运营职务。从2018年至今，莱杰先生担任Form & Fiction Ventures，Inc.（FFV）的管理合伙人，这是一家风险工作室，推出并投资于专注于社会责任倡议的初创公司和种子期公司。从2018年到2022年2月，莱杰先生在Caldll Sutter Capital，Inc.担任顾问，这是一家SEC注册的经纪交易商和投资管理公司，专注于基于价值的股票和债务证券。从2002年到2012年，Ledger先生是Tamalpais Partners，LLC的创始人和管理成员，该公司是Funds 8的普通合伙人，专注于小市值公开股票市场的特殊情况。在加入Tamalpais之前，Ledger先生曾在Fidelity Investments、Kayne Anderson Investment Management、eCompanies Venture Group和SF Sentry Investment Group担任投资组合管理职务。莱杰先生获得了康涅狄格大学的经济学学士学位。
Steve Ledger has served as a member of the Board since December 2022. Mr. Ledger is the Chief Executive Officer of the Company. Mr. Ledger served as Serina's Chief Financial Officer from June 2021 until March 2024, when he was appointed as the Interim Chief Executive Officer of the Company. The Board appointed Mr. Ledger as the Chief Executive Officer on September 9, 2024. Mr. Ledger has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early stage companies. From 2018 to the present, Mr. Ledger serves as Managing Partner of Form & Fiction Ventures, Inc. (FFV), a venture studio that launches and invests in startup and seed stage companies foced on socially responsible initiatives. From 2018 to February 2022, Mr. Ledger served as an advisor at Caldll Sutter Capital, Inc., an SEC registered broker dealer and investment management firm foced on value based equity and debt securities. From 2002 to 2012, Mr. Ledger was the founder and managing member of Tamalpais Partners, LLC, the general partner to funds foced on special situations in the small capitalization public equity markets. Prior to Tamalpais, Mr. Ledger held portfolio management roles at Fidelity Investments, Kayne Anderson Investment Management, eCompanies Venture Group, and SF Sentry Investment Group. Mr. Ledger received a B.A. in Economics from the University of Connecticut. - 史蒂夫·莱杰自2022年12月起担任董事会成员。莱杰先生是公司的首席执行官。Ledger先生于2021年6月起担任Serina的首席财务官，直至2024年3月，他被任命为公司临时首席执行官。董事会于2024年9月9日任命莱杰先生为首席执行官。Ldger先生拥有超过35年的投资者、董事会成员、顾问经验，并在早期公司担任运营职务。从2018年至今，莱杰先生担任Form & Fiction Ventures，Inc.（FFV）的管理合伙人，这是一家风险工作室，推出并投资于专注于社会责任倡议的初创公司和种子期公司。从2018年到2022年2月，莱杰先生在Caldll Sutter Capital，Inc.担任顾问，这是一家SEC注册的经纪交易商和投资管理公司，专注于基于价值的股票和债务证券。从2002年到2012年，Ledger先生是Tamalpais Partners，LLC的创始人和管理成员，该公司是Funds 8的普通合伙人，专注于小市值公开股票市场的特殊情况。在加入Tamalpais之前，Ledger先生曾在Fidelity Investments、Kayne Anderson Investment Management、eCompanies Venture Group和SF Sentry Investment Group担任投资组合管理职务。莱杰先生获得了康涅狄格大学的经济学学士学位。
- Steve Ledger has served as a member of the Board since December 2022. Mr. Ledger is the Chief Executive Officer of the Company. Mr. Ledger served as Serina's Chief Financial Officer from June 2021 until March 2024, when he was appointed as the Interim Chief Executive Officer of the Company. The Board appointed Mr. Ledger as the Chief Executive Officer on September 9, 2024. Mr. Ledger has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early stage companies. From 2018 to the present, Mr. Ledger serves as Managing Partner of Form & Fiction Ventures, Inc. (FFV), a venture studio that launches and invests in startup and seed stage companies foced on socially responsible initiatives. From 2018 to February 2022, Mr. Ledger served as an advisor at Caldll Sutter Capital, Inc., an SEC registered broker dealer and investment management firm foced on value based equity and debt securities. From 2002 to 2012, Mr. Ledger was the founder and managing member of Tamalpais Partners, LLC, the general partner to funds foced on special situations in the small capitalization public equity markets. Prior to Tamalpais, Mr. Ledger held portfolio management roles at Fidelity Investments, Kayne Anderson Investment Management, eCompanies Venture Group, and SF Sentry Investment Group. Mr. Ledger received a B.A. in Economics from the University of Connecticut.
- Steve Ledger
-
史蒂夫·莱杰自2022年12月起担任董事会成员。莱杰先生是公司的首席执行官。Ledger先生于2021年6月起担任Serina的首席财务官，直至2024年3月，他被任命为公司临时首席执行官。董事会于2024年9月9日任命莱杰先生为首席执行官。Ledger先生拥有超过35年的投资者、董事会成员、顾问经验，并在早期公司担任运营职务。从2018年至今，莱杰先生担任Form & Fiction Ventures，Inc.（FFV）的管理合伙人，这是一家风险工作室，推出并投资于专注于社会责任倡议的初创公司和种子期公司。从2018年到2022年2月，莱杰先生在Caldll Sutter Capital，Inc.担任顾问，这是一家SEC注册的经纪交易商和投资管理公司，专注于基于价值的股票和债务证券。从2002年到2012年，Ledger先生是Tamalpais Partners，LLC的创始人和管理成员，该公司是Funds 8的普通合伙人，专注于小市值公开股票市场的特殊情况。在加入Tamalpais之前，Ledger先生曾在Fidelity Investments、Kayne Anderson Investment Management、eCompanies Venture Group和SF Sentry Investment Group担任投资组合管理职务。莱杰先生获得了康涅狄格大学的经济学学士学位。
Steve Ledger has served as a member of the Board since December 2022. Mr. Ledger is the Chief Executive Officer of the Company. Mr. Ledger served as Serina’s Chief Financial Officer from June 2021 until March 2024, when he was appointed as the Interim Chief Executive Officer of the Company. The Board appointed Mr. Ledger as the Chief Executive Officer on September 9, 2024. Mr. Ledger has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early stage companies. From 2018 to the present, Mr. Ledger serves as Managing Partner of Form & Fiction Ventures, Inc. (FFV), a venture studio that launches and invests in startup and seed stage companies foced on socially responsible initiatives. From 2018 to February 2022, Mr. Ledger served as an advisor at Caldll Sutter Capital, Inc., an SEC registered broker dealer and investment management firm foced on value based equity and debt securities. From 2002 to 2012, Mr. Ledger was the founder and managing member of Tamalpais Partners, LLC, the general partner to funds 8 foced on special situations in the small capitalization public equity markets. Prior to Tamalpais, Mr. Ledger held portfolio management roles at Fidelity Investments, Kayne Anderson Investment Management, eCompanies Venture Group, and SF Sentry Investment Group. Mr. Ledger received a B.A. in Economics from the University of Connecticut. - 史蒂夫·莱杰自2022年12月起担任董事会成员。莱杰先生是公司的首席执行官。Ledger先生于2021年6月起担任Serina的首席财务官，直至2024年3月，他被任命为公司临时首席执行官。董事会于2024年9月9日任命莱杰先生为首席执行官。Ledger先生拥有超过35年的投资者、董事会成员、顾问经验，并在早期公司担任运营职务。从2018年至今，莱杰先生担任Form & Fiction Ventures，Inc.（FFV）的管理合伙人，这是一家风险工作室，推出并投资于专注于社会责任倡议的初创公司和种子期公司。从2018年到2022年2月，莱杰先生在Caldll Sutter Capital，Inc.担任顾问，这是一家SEC注册的经纪交易商和投资管理公司，专注于基于价值的股票和债务证券。从2002年到2012年，Ledger先生是Tamalpais Partners，LLC的创始人和管理成员，该公司是Funds 8的普通合伙人，专注于小市值公开股票市场的特殊情况。在加入Tamalpais之前，Ledger先生曾在Fidelity Investments、Kayne Anderson Investment Management、eCompanies Venture Group和SF Sentry Investment Group担任投资组合管理职务。莱杰先生获得了康涅狄格大学的经济学学士学位。
- Steve Ledger has served as a member of the Board since December 2022. Mr. Ledger is the Chief Executive Officer of the Company. Mr. Ledger served as Serina’s Chief Financial Officer from June 2021 until March 2024, when he was appointed as the Interim Chief Executive Officer of the Company. The Board appointed Mr. Ledger as the Chief Executive Officer on September 9, 2024. Mr. Ledger has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early stage companies. From 2018 to the present, Mr. Ledger serves as Managing Partner of Form & Fiction Ventures, Inc. (FFV), a venture studio that launches and invests in startup and seed stage companies foced on socially responsible initiatives. From 2018 to February 2022, Mr. Ledger served as an advisor at Caldll Sutter Capital, Inc., an SEC registered broker dealer and investment management firm foced on value based equity and debt securities. From 2002 to 2012, Mr. Ledger was the founder and managing member of Tamalpais Partners, LLC, the general partner to funds 8 foced on special situations in the small capitalization public equity markets. Prior to Tamalpais, Mr. Ledger held portfolio management roles at Fidelity Investments, Kayne Anderson Investment Management, eCompanies Venture Group, and SF Sentry Investment Group. Mr. Ledger received a B.A. in Economics from the University of Connecticut.
- Karen Wilson
-
Karen Wilson于2009年4月加入公司，并担任我司副总裁与首席会计主任到2011年1月。从最近的2005年到2009年，Wilson女士担任咨询公司威尔逊斯勒有限责任公司（Wilson Crisler LLC）的负责人。在这之前，她从2001年到2004年担任ViroLogic股份有限公司（ViroLogic, Inc.）的首席财务官（该公司后来被美国实验股份有限公司（Laboratory Corporation of America）收购），该公司致力于开发并商业化创新型产品，从而帮助指导并改善治疗传染疾病、癌症和其他严重疾病。加入ViroLogic前，Wilson女士从1999年到2001年担任Novare外科系统股份有限公司（Novare Surgical Systems, Inc.）运营部的首席财务官与副总裁，该公司是一家医疗设备制造商。在这之前，Wilson女士在 Deloitte & Touche有限责任合伙公司（Deloitte & Touche LLP）任职，该公司是一家专业的服务公司，最后担任的职位是高级经理，为全球的医疗与技术领域的各种客户提供服务。Wilson女士是加利福尼亚州的注册会计师，并在加利福尼亚大学伯克利分校获得商科理学学士学位。
Karen Wilson has served as a member of Elicio's Board of Directors since June 2023 and previously served as a member of Angion's Board of Directors from April 2020 until the Merger. Ms. Wilson has also been a board member of Connect Biopharma Holdings Ltd., a public company focused on improving the lives of patients living with chronic inflammatory diseases, since 2020, and Serina Therapeutics, Inc., a public company focused on a developing drug optimization technology, since 2025. Ms. Wilson also served as a member of the board of directors of LAVA Therapeutics B.V., a public company, from 2021 to 2025 (acquired) and Vaxart, Inc., a public company, from 2020 to 2022. Ms. Wilson previously served as Senior Vice President of Finance at Jazz Pharmaceuticals plc, a biopharmaceutical company, until September 2020 after serving as Principal Accounting Officer and Vice President of Finance. Prior to joining the Jazz Pharmaceuticals organization in February 2011, Ms. Wilson served as Principal Accounting Officer and Vice President of Finance at PDL BioPharma, Inc., a life sciences company. Ms. Wilson also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., a biosciences company, Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., a medical device manufacturer, and as a consultant and auditor for Deloitte & Touche LLP, a professional services firm. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley. - Karen Wilson于2009年4月加入公司，并担任我司副总裁与首席会计主任到2011年1月。从最近的2005年到2009年，Wilson女士担任咨询公司威尔逊斯勒有限责任公司（Wilson Crisler LLC）的负责人。在这之前，她从2001年到2004年担任ViroLogic股份有限公司（ViroLogic, Inc.）的首席财务官（该公司后来被美国实验股份有限公司（Laboratory Corporation of America）收购），该公司致力于开发并商业化创新型产品，从而帮助指导并改善治疗传染疾病、癌症和其他严重疾病。加入ViroLogic前，Wilson女士从1999年到2001年担任Novare外科系统股份有限公司（Novare Surgical Systems, Inc.）运营部的首席财务官与副总裁，该公司是一家医疗设备制造商。在这之前，Wilson女士在 Deloitte & Touche有限责任合伙公司（Deloitte & Touche LLP）任职，该公司是一家专业的服务公司，最后担任的职位是高级经理，为全球的医疗与技术领域的各种客户提供服务。Wilson女士是加利福尼亚州的注册会计师，并在加利福尼亚大学伯克利分校获得商科理学学士学位。
- Karen Wilson has served as a member of Elicio's Board of Directors since June 2023 and previously served as a member of Angion's Board of Directors from April 2020 until the Merger. Ms. Wilson has also been a board member of Connect Biopharma Holdings Ltd., a public company focused on improving the lives of patients living with chronic inflammatory diseases, since 2020, and Serina Therapeutics, Inc., a public company focused on a developing drug optimization technology, since 2025. Ms. Wilson also served as a member of the board of directors of LAVA Therapeutics B.V., a public company, from 2021 to 2025 (acquired) and Vaxart, Inc., a public company, from 2020 to 2022. Ms. Wilson previously served as Senior Vice President of Finance at Jazz Pharmaceuticals plc, a biopharmaceutical company, until September 2020 after serving as Principal Accounting Officer and Vice President of Finance. Prior to joining the Jazz Pharmaceuticals organization in February 2011, Ms. Wilson served as Principal Accounting Officer and Vice President of Finance at PDL BioPharma, Inc., a life sciences company. Ms. Wilson also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., a biosciences company, Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., a medical device manufacturer, and as a consultant and auditor for Deloitte & Touche LLP, a professional services firm. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.
高管简历
中英对照 | 中文 | 英文- Balkrishan Gill
Balkrishan Gill自2017年7月以来一直担任我们的董事会成员。他是Evelo Biosciences公司的总裁、首席执行官和董事会成员（2015年6月以来）。自2015年以来，吉尔博士还曾担任Flagship Pioneural（一家创新企业，构思，创建，资源和发展一流的生命科学公司）的风险合伙人。从2016年到2019年，吉尔博士担任Realm Therapeutics plc的董事会成员。吉尔博士在伦敦国王学院（King&8217；s College）获得博士学位，并在INSEAD获得工商管理硕士学位。
Balkrishan Gill,is the Executive Chairman of Serina Therapeutics since 2024. Dr. Gill was the CEO of Evelo Biosciences from 2015 to 2023. During the same period Dr. Gill was a special advisor and senior partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and develops first-in-category life sciences companies. From 2016 to 2019, Dr. Gill served on the board of directors of Realm Therapeutics PLC. Dr. Gill received his Ph.D. from King's College, London and his MBA from INSEAD.- Balkrishan Gill自2017年7月以来一直担任我们的董事会成员。他是Evelo Biosciences公司的总裁、首席执行官和董事会成员（2015年6月以来）。自2015年以来，吉尔博士还曾担任Flagship Pioneural（一家创新企业，构思，创建，资源和发展一流的生命科学公司）的风险合伙人。从2016年到2019年，吉尔博士担任Realm Therapeutics plc的董事会成员。吉尔博士在伦敦国王学院（King&8217；s College）获得博士学位，并在INSEAD获得工商管理硕士学位。
- Balkrishan Gill,is the Executive Chairman of Serina Therapeutics since 2024. Dr. Gill was the CEO of Evelo Biosciences from 2015 to 2023. During the same period Dr. Gill was a special advisor and senior partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and develops first-in-category life sciences companies. From 2016 to 2019, Dr. Gill served on the board of directors of Realm Therapeutics PLC. Dr. Gill received his Ph.D. from King's College, London and his MBA from INSEAD.
- Gregory S. Curhan
GregoryS.Curhan自2020年6月起担任我们的临时首席财务官，担任硅谷首席财务官服务公司FLG Partners，LLC FLG Partners的合伙人。在加入FLG Partners，LLC之前，Curhan先生于2016年12月至2020年1月担任Providence Medical Technology（一家风险投资支持的医疗设备制造商）的首席财务官兼高级副总裁企业发展。在此之前，Curhan先生于2012年12月至2016年12月担任财务规划公司Brighton Jones的业务开发官。Curhan先生拥有Dartmouth College经济学学士学位。
Gregory S. Curhan has served as our interim Chief Financial Officer since June 2020 through his capacity as a partner at FLG Partners, LLC FLG Partners, a Silicon Valley chief financial officer services firm. Prior to joining FLG Partners, LLC, Mr. Curhan was Chief Financial Officer and Senior Vice President Corporate Development of Providence Medical Technology, a venture-backed medical device manufacturer, December 2016 until January 2020. Prior to that, Mr. Curhan was a Business Development Officer Brighton Jones, a financial planning company, from December 2012 to December 2016. Mr. Curhan has a B.A. in Economics from Dartmouth College.- GregoryS.Curhan自2020年6月起担任我们的临时首席财务官，担任硅谷首席财务官服务公司FLG Partners，LLC FLG Partners的合伙人。在加入FLG Partners，LLC之前，Curhan先生于2016年12月至2020年1月担任Providence Medical Technology（一家风险投资支持的医疗设备制造商）的首席财务官兼高级副总裁企业发展。在此之前，Curhan先生于2012年12月至2016年12月担任财务规划公司Brighton Jones的业务开发官。Curhan先生拥有Dartmouth College经济学学士学位。
- Gregory S. Curhan has served as our interim Chief Financial Officer since June 2020 through his capacity as a partner at FLG Partners, LLC FLG Partners, a Silicon Valley chief financial officer services firm. Prior to joining FLG Partners, LLC, Mr. Curhan was Chief Financial Officer and Senior Vice President Corporate Development of Providence Medical Technology, a venture-backed medical device manufacturer, December 2016 until January 2020. Prior to that, Mr. Curhan was a Business Development Officer Brighton Jones, a financial planning company, from December 2012 to December 2016. Mr. Curhan has a B.A. in Economics from Dartmouth College.
- Randall Moreadith
Randall Moreadith是美国公民。
Randall Moreadith,served as Legacy Serina's President and Chief Executive Officer and as a member of the Legacy Serina's Board of Directors from September 2010 to March 2024. From July 2009 to December 2009, Dr. Moreadith was Chief Development Officer at Nektar Therapeutics (Nektar) where he led clinical and drug development programs that successfully moved several of the Nektar's PEGylated small molecule drugs into clinical trials for four clinical indications (ovarian, breast, cervical and colorectal cancer) and the out-licensing efforts for the approved product now known as Movantik. Prior to Nektar, Dr. Moreadith served as the Executive Vice President and Chief Medical Officer of Cardium Therapeutics, Inc. where he led the advancement of novel DNA-based adenoviral therapeutics into Phase IIb and Phase III late-stage development, from 2006 to 2008. Prior to Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. where he led the Clinical, Regulatory and Quality Assurance Groups in 2004 to 2005. From 1996 to 2003, Dr. Moreadith was co-Founder, President, and Chief Operating Officer of ThromboGenics, Ltd. (now Oxurion), a leader in the field of thrombosis drug development. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development, with one product later approved (Ocriplasmin). Dr. Moreadith received his M.D. from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. Dr. Moreadith received his Ph.D. from Johns Hopkins University and following his Fellowship in Cardiology at Duke University, he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith was a member of the faculty of the University of Texas Southwestern Medical Center.- Randall Moreadith是美国公民。
- Randall Moreadith,served as Legacy Serina's President and Chief Executive Officer and as a member of the Legacy Serina's Board of Directors from September 2010 to March 2024. From July 2009 to December 2009, Dr. Moreadith was Chief Development Officer at Nektar Therapeutics (Nektar) where he led clinical and drug development programs that successfully moved several of the Nektar's PEGylated small molecule drugs into clinical trials for four clinical indications (ovarian, breast, cervical and colorectal cancer) and the out-licensing efforts for the approved product now known as Movantik. Prior to Nektar, Dr. Moreadith served as the Executive Vice President and Chief Medical Officer of Cardium Therapeutics, Inc. where he led the advancement of novel DNA-based adenoviral therapeutics into Phase IIb and Phase III late-stage development, from 2006 to 2008. Prior to Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. where he led the Clinical, Regulatory and Quality Assurance Groups in 2004 to 2005. From 1996 to 2003, Dr. Moreadith was co-Founder, President, and Chief Operating Officer of ThromboGenics, Ltd. (now Oxurion), a leader in the field of thrombosis drug development. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development, with one product later approved (Ocriplasmin). Dr. Moreadith received his M.D. from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. Dr. Moreadith received his Ph.D. from Johns Hopkins University and following his Fellowship in Cardiology at Duke University, he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith was a member of the faculty of the University of Texas Southwestern Medical Center.
- Balkrishan Gill
Balkrishan Gill自2024年4月起担任董事会成员。吉尔博士担任董事会执行主席。2015年至2023年担任Evelo Biosciences公司创始执行主席、总裁兼首席执行官、董事会成员。Gill博士还自2015年起担任Flagship Pioneering的风险合伙人，自2017年起担任Foghorn Therapeutics的董事会成员。2016年至2019年，Gill博士在Realm Therapeutics PLC担任董事。从2006年到2015年，吉尔博士担任moksha8 Pharmaceuticals，Inc.的总裁兼首席执行官，并担任TPG Growth的合伙人。在担任这些职务之前，吉尔博士曾于1997年至2006年担任Maxygen的总裁兼首席财务官，在此之前担任Valentis和Systemix的企业发展主管。他曾在勃林格曼海姆担任Recormon全球营销联席主管、北非主管和Elecsys免疫诊断平台企业发展主管。吉尔博士是一名免疫学家，根据在Celltech所做的工作，他在伦敦国王学院获得了关于抗体药物发现开发的早期工作的博士学位。他获得了欧洲工商管理学院的工商管理硕士学位。曾在世界各地、拉丁美洲、欧洲、中东、亚洲、非洲多个国家和地区生活、工作。
Balkrishan Gill has served on the Board since April 2024. Dr. Gill serves as the Executive Chairman of the Board. He served as the founding executive chair, president and chief executive officer, and a member of the board of directors of Evelo Biosciences, Inc. from 2015 to 2023. Dr. Gill has also served as a Venture Partner at Flagship Pioneering since 2015, and a member of the board of directors of Foghorn Therapeutics from 2017. From 2016 to 2019, Dr. Gill served as a director at Realm Therapeutics PLC. From 2006 to 2015, Dr. Gill served as the president and chief executive officer of moksha8 Pharmaceuticals, Inc., and as a partner at TPG Growth. Prior to these roles Dr. Gill was president and CFO at Maxygen from 1997 to 2006 and before that head of corporate development at Valentis and at Systemix. He worked at Boehringer Mannheim as co head of Global Marketing for Recormon, head of North Africa and head of corporate development for the Elecsys Immunodiagnostic Platform. Dr. Gill is an immunologist and received his Ph.D. for early work on antibody drug discovery development from King’s College, London based on work done at Celltech. He received his M.B.A. from INSEAD. He has lived and worked in many countries and locations across the , Latin America, Europe, the Middle East, Asia, and Africa.- Balkrishan Gill自2024年4月起担任董事会成员。吉尔博士担任董事会执行主席。2015年至2023年担任Evelo Biosciences公司创始执行主席、总裁兼首席执行官、董事会成员。Gill博士还自2015年起担任Flagship Pioneering的风险合伙人，自2017年起担任Foghorn Therapeutics的董事会成员。2016年至2019年，Gill博士在Realm Therapeutics PLC担任董事。从2006年到2015年，吉尔博士担任moksha8 Pharmaceuticals，Inc.的总裁兼首席执行官，并担任TPG Growth的合伙人。在担任这些职务之前，吉尔博士曾于1997年至2006年担任Maxygen的总裁兼首席财务官，在此之前担任Valentis和Systemix的企业发展主管。他曾在勃林格曼海姆担任Recormon全球营销联席主管、北非主管和Elecsys免疫诊断平台企业发展主管。吉尔博士是一名免疫学家，根据在Celltech所做的工作，他在伦敦国王学院获得了关于抗体药物发现开发的早期工作的博士学位。他获得了欧洲工商管理学院的工商管理硕士学位。曾在世界各地、拉丁美洲、欧洲、中东、亚洲、非洲多个国家和地区生活、工作。
- Balkrishan Gill has served on the Board since April 2024. Dr. Gill serves as the Executive Chairman of the Board. He served as the founding executive chair, president and chief executive officer, and a member of the board of directors of Evelo Biosciences, Inc. from 2015 to 2023. Dr. Gill has also served as a Venture Partner at Flagship Pioneering since 2015, and a member of the board of directors of Foghorn Therapeutics from 2017. From 2016 to 2019, Dr. Gill served as a director at Realm Therapeutics PLC. From 2006 to 2015, Dr. Gill served as the president and chief executive officer of moksha8 Pharmaceuticals, Inc., and as a partner at TPG Growth. Prior to these roles Dr. Gill was president and CFO at Maxygen from 1997 to 2006 and before that head of corporate development at Valentis and at Systemix. He worked at Boehringer Mannheim as co head of Global Marketing for Recormon, head of North Africa and head of corporate development for the Elecsys Immunodiagnostic Platform. Dr. Gill is an immunologist and received his Ph.D. for early work on antibody drug discovery development from King’s College, London based on work done at Celltech. He received his M.B.A. from INSEAD. He has lived and worked in many countries and locations across the , Latin America, Europe, the Middle East, Asia, and Africa.
- Steve Ledger
史蒂夫·莱杰自2022年12月起担任董事会成员。莱杰先生是公司的首席执行官。Ledger先生于2021年6月起担任Serina的首席财务官，直至2024年3月，他被任命为公司临时首席执行官。董事会于2024年9月9日任命莱杰先生为首席执行官。Ledger先生拥有超过35年的投资者、董事会成员、顾问经验，并在早期公司担任运营职务。从2018年至今，莱杰先生担任Form & Fiction Ventures，Inc.（FFV）的管理合伙人，这是一家风险工作室，推出并投资于专注于社会责任倡议的初创公司和种子期公司。从2018年到2022年2月，莱杰先生在Caldll Sutter Capital，Inc.担任顾问，这是一家SEC注册的经纪交易商和投资管理公司，专注于基于价值的股票和债务证券。从2002年到2012年，Ledger先生是Tamalpais Partners，LLC的创始人和管理成员，该公司是Funds 8的普通合伙人，专注于小市值公开股票市场的特殊情况。在加入Tamalpais之前，Ledger先生曾在Fidelity Investments、Kayne Anderson Investment Management、eCompanies Venture Group和SF Sentry Investment Group担任投资组合管理职务。莱杰先生获得了康涅狄格大学的经济学学士学位。
Steve Ledger has served as a member of the Board since December 2022. Mr. Ledger is the Chief Executive Officer of the Company. Mr. Ledger served as Serina's Chief Financial Officer from June 2021 until March 2024, when he was appointed as the Interim Chief Executive Officer of the Company. The Board appointed Mr. Ledger as the Chief Executive Officer on September 9, 2024. Mr. Ledger has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early stage companies. From 2018 to the present, Mr. Ledger serves as Managing Partner of Form & Fiction Ventures, Inc. (FFV), a venture studio that launches and invests in startup and seed stage companies foced on socially responsible initiatives. From 2018 to February 2022, Mr. Ledger served as an advisor at Caldll Sutter Capital, Inc., an SEC registered broker dealer and investment management firm foced on value based equity and debt securities. From 2002 to 2012, Mr. Ledger was the founder and managing member of Tamalpais Partners, LLC, the general partner to funds foced on special situations in the small capitalization public equity markets. Prior to Tamalpais, Mr. Ledger held portfolio management roles at Fidelity Investments, Kayne Anderson Investment Management, eCompanies Venture Group, and SF Sentry Investment Group. Mr. Ledger received a B.A. in Economics from the University of Connecticut.- 史蒂夫·莱杰自2022年12月起担任董事会成员。莱杰先生是公司的首席执行官。Ledger先生于2021年6月起担任Serina的首席财务官，直至2024年3月，他被任命为公司临时首席执行官。董事会于2024年9月9日任命莱杰先生为首席执行官。Ledger先生拥有超过35年的投资者、董事会成员、顾问经验，并在早期公司担任运营职务。从2018年至今，莱杰先生担任Form & Fiction Ventures，Inc.（FFV）的管理合伙人，这是一家风险工作室，推出并投资于专注于社会责任倡议的初创公司和种子期公司。从2018年到2022年2月，莱杰先生在Caldll Sutter Capital，Inc.担任顾问，这是一家SEC注册的经纪交易商和投资管理公司，专注于基于价值的股票和债务证券。从2002年到2012年，Ledger先生是Tamalpais Partners，LLC的创始人和管理成员，该公司是Funds 8的普通合伙人，专注于小市值公开股票市场的特殊情况。在加入Tamalpais之前，Ledger先生曾在Fidelity Investments、Kayne Anderson Investment Management、eCompanies Venture Group和SF Sentry Investment Group担任投资组合管理职务。莱杰先生获得了康涅狄格大学的经济学学士学位。
- Steve Ledger has served as a member of the Board since December 2022. Mr. Ledger is the Chief Executive Officer of the Company. Mr. Ledger served as Serina's Chief Financial Officer from June 2021 until March 2024, when he was appointed as the Interim Chief Executive Officer of the Company. The Board appointed Mr. Ledger as the Chief Executive Officer on September 9, 2024. Mr. Ledger has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early stage companies. From 2018 to the present, Mr. Ledger serves as Managing Partner of Form & Fiction Ventures, Inc. (FFV), a venture studio that launches and invests in startup and seed stage companies foced on socially responsible initiatives. From 2018 to February 2022, Mr. Ledger served as an advisor at Caldll Sutter Capital, Inc., an SEC registered broker dealer and investment management firm foced on value based equity and debt securities. From 2002 to 2012, Mr. Ledger was the founder and managing member of Tamalpais Partners, LLC, the general partner to funds foced on special situations in the small capitalization public equity markets. Prior to Tamalpais, Mr. Ledger held portfolio management roles at Fidelity Investments, Kayne Anderson Investment Management, eCompanies Venture Group, and SF Sentry Investment Group. Mr. Ledger received a B.A. in Economics from the University of Connecticut.
- Gregory S. Curhan
Gregory S. Curhan，自2020年2月起担任FLG Partners的合伙人，自2020年以来，Curhan先生还担任Curevo Vaccines的首席财务官，Curevo Vaccines是一家总部位于西雅图的私营风险投资支持的生物技术公司，专注于传染病免疫学。从2020年6月至2023年6月，Curhan先生还担任Angion Biomedica Corp.的首席财务官。在加入FLG Partners之前，Curhan先生是Providence Medical Technology的首席财务官和企业发展高级副总裁，Providence Medical Technology是一家风险投资支持的医疗设备制造商，自2016年12月至2020年1月。在此之前，Curhan先生于2012年12月至2016年12月在财务规划公司Brighton Jones担任业务发展官员。Curhan先生拥有达特茅斯学院的经济学学士学位。
Gregory S. Curhan,has been a partner at FLG Partners, since February 2020, and since 2020 Mr. Curhan has also served as the CFO of Curevo Vaccines, a Seattle-based private venture backed biotech focused on infectious disease immunology. From June 2020 until June 2023, Mr. Curhan also served as the Chief Financial Officer of Angion Biomedica Corp. Prior to joining FLG Partners, Mr. Curhan was Chief Financial Officer and Senior Vice President Corporate Development of Providence Medical Technology, a venture-backed medical device manufacturer from December 2016 until January 2020. Prior to that, Mr. Curhan was a Business Development Officer at Brighton Jones, a financial planning company, from December 2012 to December 2016. Mr. Curhan has a B.A. in conomics from Dartmouth College.- Gregory S. Curhan，自2020年2月起担任FLG Partners的合伙人，自2020年以来，Curhan先生还担任Curevo Vaccines的首席财务官，Curevo Vaccines是一家总部位于西雅图的私营风险投资支持的生物技术公司，专注于传染病免疫学。从2020年6月至2023年6月，Curhan先生还担任Angion Biomedica Corp.的首席财务官。在加入FLG Partners之前，Curhan先生是Providence Medical Technology的首席财务官和企业发展高级副总裁，Providence Medical Technology是一家风险投资支持的医疗设备制造商，自2016年12月至2020年1月。在此之前，Curhan先生于2012年12月至2016年12月在财务规划公司Brighton Jones担任业务发展官员。Curhan先生拥有达特茅斯学院的经济学学士学位。
- Gregory S. Curhan,has been a partner at FLG Partners, since February 2020, and since 2020 Mr. Curhan has also served as the CFO of Curevo Vaccines, a Seattle-based private venture backed biotech focused on infectious disease immunology. From June 2020 until June 2023, Mr. Curhan also served as the Chief Financial Officer of Angion Biomedica Corp. Prior to joining FLG Partners, Mr. Curhan was Chief Financial Officer and Senior Vice President Corporate Development of Providence Medical Technology, a venture-backed medical device manufacturer from December 2016 until January 2020. Prior to that, Mr. Curhan was a Business Development Officer at Brighton Jones, a financial planning company, from December 2012 to December 2016. Mr. Curhan has a B.A. in conomics from Dartmouth College.
- Srini Tenjarla
Srini Tenjarla，截至2024年7月担任Serina的CMC和配方高级副总裁。Tenjarla博士拥有30多年if生命科学经验。.在加入Serina Therapeutics之前，Tenjarla博士曾在武田制药担任副总裁兼药物产品开发和过程化学开发/药物科学外包主管。在担任这一职务期间，他为全球团队提供技术和战略领导，通过产品验证和PAI准备情况，监督从第1阶段开始的适合阶段的开发。在武田任职之前，Tenjarla博士曾在Shire Pharmaceuticals担任过多个领导职务，最终担任药物科学副总裁。Tenjarla博士在推进项目通过临床阶段到NDA/BLA提交和批准方面有着良好的记录。
Srini Tenjarla,has served as Serina's Senior Vice President of CMC and Formulation as of July 2024. Dr. Tenjarla has more than 30 years experience if Life sciences. .Prior to joining Serina Therapeutics, Dr. Tenjarla served as Vice President and Head of Drug Product Development and Process Chemistry Development/Outsourcing in Pharmaceutical Sciences at Takeda Pharmaceuticals. In this role, he provided technical and strategic leadership to global teams, overseeing phase-appropriate development from Phase 1 through product validation and PAI readiness. Prior to his tenure at Takeda, Dr. Tenjarla held several leadership roles at Shire Pharmaceuticals, culminating in his position as Vice President of Pharmaceutical Sciences. Dr. Tenjarla has a proven track record in advancing programs through clinical phases to NDA/BLA submission and approval.- Srini Tenjarla，截至2024年7月担任Serina的CMC和配方高级副总裁。Tenjarla博士拥有30多年if生命科学经验。.在加入Serina Therapeutics之前，Tenjarla博士曾在武田制药担任副总裁兼药物产品开发和过程化学开发/药物科学外包主管。在担任这一职务期间，他为全球团队提供技术和战略领导，通过产品验证和PAI准备情况，监督从第1阶段开始的适合阶段的开发。在武田任职之前，Tenjarla博士曾在Shire Pharmaceuticals担任过多个领导职务，最终担任药物科学副总裁。Tenjarla博士在推进项目通过临床阶段到NDA/BLA提交和批准方面有着良好的记录。
- Srini Tenjarla,has served as Serina's Senior Vice President of CMC and Formulation as of July 2024. Dr. Tenjarla has more than 30 years experience if Life sciences. .Prior to joining Serina Therapeutics, Dr. Tenjarla served as Vice President and Head of Drug Product Development and Process Chemistry Development/Outsourcing in Pharmaceutical Sciences at Takeda Pharmaceuticals. In this role, he provided technical and strategic leadership to global teams, overseeing phase-appropriate development from Phase 1 through product validation and PAI readiness. Prior to his tenure at Takeda, Dr. Tenjarla held several leadership roles at Shire Pharmaceuticals, culminating in his position as Vice President of Pharmaceutical Sciences. Dr. Tenjarla has a proven track record in advancing programs through clinical phases to NDA/BLA submission and approval.